Clinical case: chronic skin fold candidiasis against the background of treatment with an interleukin-17A inhibitor in a patient with extensive severe psoriasis
- Authors: Svechnikova E.V1,2, Zhufina E.V.1
-
Affiliations:
- Polyclinic № 1 of the Administrative Department of the President of the Russian Federation
- Novosibirsk State Medical University
- Issue: Vol 29, No 8 (2022)
- Pages: 109-115
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321053
- DOI: https://doi.org/10.18565/pharmateca.2022.8.109-114
- ID: 321053
Cite item
Open Access
Access granted
Abstract
Background. Psoriatic disease is a concept that combines a complex of immunological disorders that lead to the development of a number of symptoms of damage to the skin, joints, cardiovascular, nervous, excretory, endocrine systems and metabolic disorders. This article discusses the main components in the immunopathogenesis of psoriasis, associated primarily with T-helper 17 cells (TH17)? and the interleukin-23 (IL-23) pathway, as well as the relationship between the severity of the course of psoriasis and the risks of developing infectious complications and their possible pathogenetic mechanisms. Description of the clinical case. A clinical case of a patient with a severe course of psoriasis, concomitant comorbid pathology, who received genetically engineered biological therapy with an IL-17 inhibitor and developed secondary inefficiency and an infectious complication, as a result of which the patient was transferred to genetically engineered biological therapy with a drug from the IL-23 inhibitor group, is presented. Conclusion. The risk of co-infections may increase with the use of certain immunosuppressive drugs, therefore, when choosing a drug for the treatment of a patient with psoriasis, it is recommended to carefully examine patient for possible latent systemic infections and take into account the presence of concomitant diseases.
Full Text
About the authors
E. V Svechnikova
Polyclinic № 1 of the Administrative Department of the President of the Russian Federation; Novosibirsk State Medical University
Email: elene-elene@bk.ru
Dr. Sci. (Med.), Professor at the Department Moscow, Russia; Novosibirsk, Russia
Elena V. Zhufina
Polyclinic № 1 of the Administrative Department of the President of the Russian FederationMoscow, Russia
References
- Thakur V., Mahajan R. Novel Therapeutic Target(s) for Psoriatic Disease. Front Med. 2022;9:712313. doi: 10.3389/fmed.2022.712313.
- Armstrong A.W., Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323:1945-60. doi: 10.1001/jama.2020.4006.
- Yamauchi P.S., Bagel J. Next-generation biologics in the management of plaque psoriasis: A literature review of IL-17 inhibition. J Drugs Dermatol. 2015;14(3):244-53.
- Jeon C., Sekhon S., Yan D., et al. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Human Vaccine. Immunother. 2017;13(10):2247-59. doi: 10.1080/21645515.2017.1356498.
- Yiu Z.Z., Griffiths C.E.Interleukin 17-A inhibition in the treatment of psoriasis. Expert Rev Clin Immunol. 2016;12:1-4. doi: 10.1586/1744666X.2016.1112739.
- Demir A.N., Ucar I., Kacar C., et al. Candida Infection in a Patient With Ankylosing Spondylitis Under Treatment With Secukinumab. Arch Rheumatol. 2020;35(1):151-53. doi: 10.5606/ArchRheumatol.2020.7545.
- Saunte D.M., Mrowietz U., Puig L., Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management Br J Dermatol. 2017;177:47-62. doi: 10.1111/bjd.15015.
- Siegel S.A.R., Winthrop K.L. In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis. Curr Rheumatol Rep. 2019;21:36. doi: 10.1007/s11926-019-0832-y.
- Abuabara K., Azfar R.S., Shin D.B., et al. Cause-specific Mortality in Patients with Severe Psoriasis: A Population-based Cohort Study in the U.K. Brit J Dermatol. 2010;163:586-92. doi: 10.1111/j.1365-2133.2010.09941.x.
- Yiu Z.Z.N., Parisi R., Lunt M., et al. Risk of Hospitalization and Death Due to Infection in People with Psoriasis: A Population-based Cohort Study Using the Clinical Practice Research Datalink. Brit J Dermatol. 2021;184:78-86. doi: 10.1111/bjd.19052.
- Takeshita J., Shin D.B., Ogdie A., et al. Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom. J Investig Dermatol. 2018;138:1726-35. doi: 10.1016/j.jid.2018.01.039.
- Deodhar A., Mease P.J., McInnes I.B., et al. Long-Term Safety of Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Integrated Pooled Clinical Trial and Post-Marketing Surveillance Data. Arthr Res Ther. 2019;21:888. doi: 10.1186/s13075-019-1882-2.
- Motolese A., Ceccarelli M., Macca L., et al. Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease. Biomed. 2022;10:228. doi: 10.3390/biomedicines10020228.
- Pettas E., Savva V., Theofilou V.I., et al. Oral Candida Infection in Psoriatic Patients Treated with IL-17A Inhibitors: Report of 3 Cases and a Comprehensive Review of the Literature. Diagnostics. 2022;12:3. doi: 10.3390/diagnostics 12010003.
Supplementary files
